PHAXIAM Therapeutics S.A. (PHXM) Stock Analysis
DELISTED
What happened to PHAXIAM Therapeutics S.A. (PHXM) stock?
PHAXIAM Therapeutics S.A. (PHXM) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
Market cap $19.9M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
PHAXIAM Therapeutics S.A. (PHXM). PHAXIAM Therapeutics S.A. is a biopharmaceutical company focusing on developing treatments for resistant bacterial infections. Their lead product, eryaspase, is in Phase 3 clinical development for second-line pancreatic cancer.
Last analyzed: Mar 18, 2026PHAXIAM Therapeutics S.A. (PHXM) Healthcare & Pipeline Overview
PHAXIAM Therapeutics S.A. ADR Information Sponsored
PHAXIAM Therapeutics S.A. (PHXM) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy PHXM shares?
No. PHXM stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for PHXM elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PHXM stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to PHAXIAM Therapeutics S.A.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.